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All-oral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates 
of 95% or more, represent a major clinical advance. However, the high list price of DAAs has 
led many governments to restrict their reimbursement. We reviewed the availability of, and 
national criteria for, interferon-free DAA reimbursement among countries in the European 
Union and European Economic Area, and Switzerland. Reimbursement documentation was 
reviewed between Nov 18, 2016, and Aug 1, 2017. Primary outcomes were fibrosis stage, 
drug or alcohol use, prescriber type, and HIV co-infection restrictions. Among the 35 
European countries and jurisdictions included, the most commonly reimbursed DAA was 
ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin (33 [94%] 
countries and jurisdictions). 16 (46%) countries and jurisdictions required patients to have 
fibrosis at stage F2 or higher, 29 (83%) had no listed restrictions based on drug or alcohol 
use, 33 (94%) required a specialist prescriber, and 34 (97%) had no additional restrictions 
for people co-infected with HIV and hepatitis C virus. These findings have implications for 
meeting WHO targets, with evidence of some countries not following the 2016 hepatitis C 





Over 71 million people (range 63–79 million) are infected with chronic hepatitis C virus 
(HCV) globally, with about 704 000 HCV-related deaths each year (range 652 100–769 600) 
(1–3).  Compared with pegylated interferonbased therapies, all-oral direct-acting antiviral 
drugs (DAAs) for HCV are more tolerable and achieve viral cure in 95% or more patients, 
which represents one of the best clinical advances in recent decades (4). Broad uptake of 
DAAs could substantially reduce the global HCV disease burden, particularly HCV-related 
mortality and morbidity (5–7). However, the high list price of DAA therapies in some 
countries has led many governments (8,9) to restrict patient reimbursement based on liver 
fibrosis severity, drug and alcohol use, and prescriber type. A 2014 study of Medicaid 
reimbursement criteria for sofosbuvir in the USA showed that criteria varied by state 
jurisdiction (8). Most states (88%) had restrictions based on drug and alcohol use, 74% 
required evidence of advanced fibrosis (≥stage F3), 66% had prescriber limitations, and 25% 
required people co-infected with HIV and HCV to have suppressed HIV RNA levels or be 
receiving antiretroviral therapy (8).  
 
An updated reimbursement study by Ooka and colleagues (10) showed that, overall, 
restrictions had lessened over a 2-year period (2014–16). For example, 22 states required 
evidence of advanced fibrosis (≥F3) in 2016, compared with 31 states in 2014. However, this 
updated study also highlighted that several of the criteria for reimbursement are inconsistent 
with clinical recommendations, which state that all people who want to be treated and have 
no treatment contraindications should be considered for HCV therapy (11–13). In Europe, 
about 3.2 million people (range 2.1 - 3.8 million) are estimated to have chronic HCV infection 
(14).  In most European countries, injection drug use is the most common route of HCV 
transmission (15–17).  
 
Although HCV incidence is decreasing overall in Europe, liver-related deaths, and the 
proportions of people with decompensated cirrhosis and hepatocellular carcinoma among 
individuals infected with HCV, are projected to increase 20–30% by 2030 if broad access to 
DAAs is not achieved (14). This estimation must be considered in the context of 2030 HCV 
global targets set by WHO, which propose that HCV incidence is reduced by 80%, that 90% 
of people with HCV are diagnosed, that 80% of people with HCV are treated, and that HCV-
related mortality is reduced by 65% (18). To meet WHO targets, it is crucial that countries 
use strategies that optimise uptake of DAAs, such as minimising restrictions for DAA 
reimbursement. We aimed to review the availability of interferon-free DAAs among countries 
in the European Union or European Economic Area, and Switzerland, and to review national 





We reviewed the availability of reimbursed DAAs and national criteria for DAA 
reimbursement among countries in the European Union or European Economic Area 
(including England, Northern Ireland, Scotland, and Wales as separate jurisdictions) and 
Switzerland. Reimbursement criteria were reviewed for the following DAA regimens: 
sofosbuvir with ribavirin; sofosbuvir and ledipasvir with or without ribavirin; sofosbuvir 
and velpatasvir with or without ribavirin; ombitasvir, paritaprevir, and ritonavir, with 
dasabuvir, and with or without ribavirin; elbasvir and grazoprevir with or without ribavirin; and 
sofosbuvir and daclatasvir with or without ribavirin. Between Nov 18, 2016, and Aug 1, 2017, 
most data were extracted from publicly available documentation from government websites 
and online drug formularies (appendix p 1). We also collected additional documentation 
(eg, national HCV guidelines) when available (appendix p 3). If it was difficult to recover 
information, one of three study authors (ADM, EBC, or SNi) contacted the study author from 
the country of interest to request access.  
 
Given that most documents were published in a language other than English, authors of this 
study that were from these countries were crucial to identify documents of relevance. Three 
authors (ADM, EBC, or SNi) did independent document searches to further support the 
search findings. We also contacted authors of this study from each country to provide 
clarification if there were inconsistencies between documents, or if additional documents 
were needed. If documents could not be located, this finding was categorised as not 
available. Information was reviewed to determine the availability of reimbursed HCV DAAs in 
Europe. Categories were Yes or No. If an individual was eligible to receive a specific therapy 
(eg, sofosbuvir and daclatasvir with or without ribavirin) but this therapy was not reimbursed, 
this event was categorised as No.  
 
Based on previous HCV DAA reimbursement studies (8,9) we assessed the following criteria 
restrictions: minimum fibrosis stage (METAVIR or equivalent), drug or alcohol use, 
prescriber type, and co-infection with HIV. If information for a specific criterion was not 
reported with the other criteria, it was categorised as none listed. Fibrosis stage was 
categorised as: no restriction, F2, F3, F4, other, none listed, or not available. Fibrosis stage 
could be assessed through liver biopsy, transient elastography, biomedical markers, or a 
combination of these. We anticipated that, in many countries, patients with extrahepatic 
manifestations (eg, cryoglobulinaemia) would be subject to different criteria than 
asymptomatic patients (eg, different fibrosis stage restrictions). Given that the primary 
interest of this study was to assess criteria applicable to most patients, we recorded the 
minimum fibrosis stage for asymptomatic patients. Drug or alcohol use was categorised as: 
prioritised, no restrictions, additional restrictions, none listed, or not available. Prioritised 
meant that people with drug or alcohol use dependencies had fewer restrictions for access 
to reimbursed DAAs than individuals without drug or alcohol use dependencies. No 
restrictions meant that people with drug or alcohol use dependencies could receive 
reimbursed DAAs; for example, a person who currently injected drugs (or had a history of 
injection use) could be offered DAAs. Additional restrictions meant that individuals with drug 
or alcohol use dependencies needed to fulfil further criteria before being eligible for DAA 
reimbursement. On the basis of previous evidence (8, 10) we anticipated that one example 
of a drug or alcohol use restriction that might be used in European countries would be a 
mandatory period of abstinence from substance use before therapy (eg, a 6-month period of 
abstinence from drug use). In addition to this restriction, we noted any other drug or alcohol 
use restrictions that were listed in reimbursement criteria. Prescriber type categories were: 
no restriction, specialist only, none listed, and not available. No restriction meant that a 
health-care provider other than a specialist (eg, general practitioner) could prescribe 
interferon-free HCV DAAs. Specialist only meant that the criteria required that the prescriber 
worked within a specialised field. Options included, but were not limited to, hepatologist, 
infectious disease specialist, internal medicine specialist, and gastroenterologist. 
 
If a country or jurisdiction allowed a general practitioner to prescribe HCV DAAs but these 
therapies were not reimbursed, then this event was categorised as a restriction (ie, specialist 
only), because we were specifically interested in access to reimbursed therapies. Moreover, 
given that the study focus was specific to prescribing, whether a general practitioner or nurse 
practitioner could treat and monitor a patient who received interferon-free HCV DAAs was 
not recorded. HIV co-infection categories were: prioritised, eligible, none listed, and not 
available. Prioritised meant that people with HIV and HCV co-infection were given priority for 
treatment reimbursement (ie, had fewer reimbursement restrictions) over individuals with 
HCV alone. Eligible meant that people with HIV and HCV co-infection were subject to the 
same restriction criteria as individuals with HCV alone. Other was a possible category for 
any of the restriction criteria, when appropriate. Data were organised by use of descriptive 
statistics with Microsoft Excel (version 2010). Using separate Excel spreadsheets, two study 
authors (ADM and EBC) categorised the outcome criteria of about half of the European 
countries and jurisdictions each. Once completed, the same two study authors 
independently cross-checked each other’s categorisation against the documentation. 
Relevant study authors were then contacted when further clarification was needed to resolve 





All European countries and jurisdictions (100%, n=35) provided reimbursement for DAAs to 
treat HCV infection. As of Aug 1, 2017, the most commonly reimbursed therapy was  
ombitasvir, paritaprevir, and ritonavir, with dasabuvir, and with or without ribavirin 
(reimbursement available in 33 [94%] countries). Sofosbuvir and daclatasvir with or without 
ribavirin was the least likely to be reimbursed (22 [63%] countries). Most countries 
reimbursed sofosbuvir and ledipasvir with or without ribavirin (31 [89%] countries), and  
elbasvir and grazoprevir with or without ribavirin (32 [91%] countries), and 26 (74%) 
countries reimbursed sofosbuvir and velpatasvir with or without ribavirin, while 29 (83%) 
countries reimbursed sofosbuvir with ribavirin. Some countries, namely Estonia, Latvia, 
Lithuania, Malta, and Romania, had comparatively fewer therapeutic options than did other 
countries that reimbursed all HCV DAAs (figure 1). 16 (46%) countries and jurisdictions 
required evidence of fibrosis of at least stage F2 (METAVIR or equivalent). Specifically, 10 
(29%) countries and jurisdictions required a minimum stage of F2; five (14%) countries 
required a minimum fibrosis stage of F3; one (3%) country (Malta) required a minimum 
fibrosis stage of F4; 13 (37%) countries had no fibrosis stage restrictions; and six (17%) 
countries had an additional requirement (eg, point system regardless of fibrosis stage; figure 
2). In some countries, fibrosis stage was dependent on genotype. For example, Norway had 
no fibrosis stage restrictions for genotypes 1 and 4 (figure 1). The clinical recommendation in 
Norway was also age-dependent. People who were infected with genotype 2 or 3, were 
younger than 40 years, and did not have cirrhosis, were offered peginterferon plus ribavirin 
for 12 weeks as the first line of therapy (19, 20). In Austria, Switzerland, and Liechtenstein, 
the HCV DAAs prescribed depended on the fibrosis stage. For example, sofosbuvir and 
ledipasvir with or without ribavirin, and sofosbuvir and velpatasvir with or without ribavirin 
had a minimum requirement of fibrosis stage F2; whereas elbasvir and grazoprevir with or 
without ribavirin had no restrictions based on fibrosis stage for individuals infected with 
genotypes 1 and 4 (21–24).  
 
Although 29 (83%) countries and jurisdictions had no listed restrictions for drug or alcohol 
use, six (17%) countries required abstinence from drug and alcohol use before treatment 
(≥6-month abstinence; figure 3). This restriction could include, but was not limited to, 
toxicological reports (eg, urine drug screening) every 3 months while taking DAAs to verify 
abstinence, as required in Croatia (appendix p 2). To receive reimbursed therapy in 
Hungary, people actively using injection drugs or alcohol needed a psychiatrist consultation 
to support their capability and compliance for treatment and confirm no active injection drug 
use. In Romania, people with HIV and HCV co-infection had to have a negative drug test to 
receive reimbursed therapy; this restriction did not seem to apply to people with HCV alone. 
In Liechtenstein and Switzerland, people who inject drugs were prioritised for treatment with 
no fibrosis stage restriction (although fibrosis stage restrictions were in place in these 
countries for non-drug users).  
 
Most countries and jurisdictions in Europe (33 [94%] countries) required a specialist, most 
often a gastroenterologist, hepatologist, internal medicine specialist, or infectious disease 
specialist, to prescribe reimbursed DAAs for HCV (figure 4). In England, general 
practitioners could prescribe DAAs, although specialist input from a local multi-disciplinary 
committee was required. Operational Delivery Networks, established by the National Health 
Service in England, are committees that oversee patient care and HCV treatment, determine 
who can prescribe DAAs for HCV, and prioritises patients for therapy. In Germany, all 
general practitioners could prescribe reimbursed DAAs for HCV.  
 
Certain countries, such as France, allowed general practitioners trained in HCV care to 
monitor patients once HCV therapy had started. However, France still required a specialist to 
prescribe DAAs. Some countries provided a list of specialist prescribers that patients needed 
to visit to receive a prescription for DAAs, whereas other countries—Austria, Czech 
Republic, Slovakia, and Slovenia—provided a list of specialist centres that dispense DAAs. 
Therefore, not all specialists were able to prescribe DAAs for HCV. Lastly, most European 
countries and jurisdictions (34 [97%] countries) had no additional restrictions for people co-
infected with HIV and HCV. Among the 22 countries that had minimum fibrosis stage 
restrictions (including those in the category Other) for individuals infected with HCV alone, 
nine (41%) of these countries (Belgium, Croatia, Czech Republic, Greece, Liechtenstein, 
Malta, Slovakia, Slovenia, and Switzerland) had no fibrosis stage restrictions for people co-
infected with HIV and HCV; hence, these patients were prioritised for treatment (figure 5). In 





This study demonstrated several similarities concerning access and reimbursement 
restrictions for DAAs in Europe. Restrictions based on specialist prescription were almost 
universal, with 94% (n=33) of countries requiring a specialist to prescribe DAAs. Disease-
based restrictions were common, with nearly half of countries and jurisdictions restricting 
DAAs to people with substantial liver disease (≥F2). Furthermore, six (17%) countries 
required patient abstinence from drug or alcohol use to qualify for reimbursed therapies. 
These restrictions are not in agreement with the 2016 European Association for the Study of 
Liver (EASL) recommendations on the treatment of hepatitis C, which state that all patients 
without contraindications to therapy should be offered treatment.12 Additionally, these 
restrictions will need to be minimised to meet the WHO target of eliminating viral hepatitis as 
a major public health threat by 2030 (18). To our knowledge, this is the first study to review 
HCV DAA reimbursement restrictions in Europe, and its primary findings have the potential 
to influence clinical practice and policy. Similar studies on DAA restrictions have been used 
in legal and advocacy efforts to remove (or reduce) DAA reimbursement restrictions in 
Canada and the USA.8–10 A follow-up study of reimbursement in the USA showed that 
states decreased reimbursement restrictions over a 2-year period.8,10 This finding highlights 
the importance of collecting data for Europe, to provide a baseline from which to compare 
DAA access in the coming years. A follow-up study on DAA access and restrictions in 
Europe would be beneficial.  
 
There were some limitations in the present study. Given that there was no systematic 
repository or standardised system for the collation of reimbursement restriction information, 
we relied on an extensive selection of documents and ongoing consultation with study 
authors to verify the accuracy of data. This study only evaluated written restrictions, and the 
prescribing practices of clinicians might differ from reimbursement criteria. For example, 
among countries that have no listed drug use restriction, people who inject drugs could be 
much less likely to be offered DAAs. Further, if additional restrictions were reviewed, even 
greater reimbursement discrepancies across countries and jurisdictions might have been 
revealed. For example, in Belgium, both an elastography test and biomarker score (or 
alternatively, a liver biopsy) were required to assess fibrosis stage (25). Countries might also 
differ on policies for re-treatment.  
 
Moreover, the present study did not review variability within countries. People who reside in 
rural areas or do not have private health insurance plans might find it more difficult to access 
reimbursed therapies. This topic warrants further study. Research on heterogeneity in 
health-care systems in Europe, specifically how medication coverage (with varying 
deductible or co-pay arrangements) affects treatment access at the patient level, is also 
needed. With respect to reimbursement restrictions, we did not specifically investigate the 
distinction between access and choice. In some countries, the available regimens might 
have been limited by conditions put in place by the reimbursement agency, which might 
have restricted the selection of DAAs that physicians could choose to prescribe. Lastly, 
timeliness of data was a limitation in this study.  
 
Although efforts were made to include the most current information, online information and 
documentation concerning DAA availability and reimbursement restrictions frequently 
changed as therapies became approved and governments negotiated new agreements with 
pharmaceutical companies. We did not contact government ministries to verify information, 
which is a notable limitation of this study. Nevertheless, this study provides an accurate 
assessment of reimbursement restrictions in Europe as of Aug 1, 2017. The considerable 
heterogeneity in DAA availability and reimbursement restrictions observed in Europe is 
consistent with previous studies that have evaluated regional differences in reimbursement 
in Canada (9) and the USA (8, 10).  
 
Notably, 33 (94%) countries and jurisdictions in Europe required a specialist to prescribe 
DAAs compared with up to 42% of provinces and territories in Canada (9) and 67% of states 
in the USA (10). Even in European countries and jurisdictions where primary care providers 
can prescribe DAAs, restrictions are in place through managed care networks (eg, in 
England) or physicians are concerned with medical liability claims (eg, in Germany). In 
Australia, all medical providers (including primary care clincians and drug or alcohol 
clinicians) can prescribe DAAs. Less experienced prescribers are required to consult a 
gastroenterologist, hepatologist, or infectious disease specialist to confirm the 
appropriateness of DAA treatment. Under this system, an increasing proportion of DAA 
prescriptions are completed by primary care and non-specialist providers (26). Several 
factors will probably affect current and future prescriber patterns, including involvement of 
nonspecialists. Countries with more concentrated geography (less rural or remote regions), 
well developed specialist treatment centres with extensive referral pathways, and fewer 
highly marginalised patients, might not require substantial involvement from non-specialists. 
Countries that expand prescriber protocols to include non-specialists can be encouraged by 
evidence that HCV treatment outcomes are similar between primary care providers and 
specialists (27, 28).  
 
The WHO viral hepatitis strategy states that everyone living with viral hepatitis should have 
access to safe, affordable, and effective care (18). However, nearly half of European 
countries have restricted DAA reimbursement to people with, at minimum, moderate fibrosis 
(≥F2), which is also inconsistent with the 2016 EASL recommendations on the treatment of 
hepatitis C (12). The restriction of DAA treatment to patients with more advanced liver 
disease (and other criteria such as genotype and age, as seen in Norway) is a form of 
prioritisation in the context of high DAA pricing related to potential health budget concerns.  
 
These constraints are, presumably, an interim strategy while countries await the 
development of further treatment infrastructure and declines in DAA pricing. Restrictions 
regarding stage of liver disease will probably be removed in many countries in the near 
future, as happened in Spain in June, 2017. Successful treatment of HCV infection reduces 
progression of liver disease (29) and decreases all-cause mortality in people with advanced 
liver disease (30). Treatment of those with the greatest risk of transmission (eg, people who 
inject drugs) helps to prevent onward HCV transmission (31). As such, increasing access to 
DAA therapy will yield both individual and public health benefits. 17% of European countries 
restricted access to DAAs among people with recent drug or alcohol use.  
 
Perceptions about poor adherence resulting from ongoing substance use and risk of re-
infection are often put forward as reasons to withhold HCV therapy from people who inject 
drugs (32, 33). A study (32) of HCV practitioners (72% were gastroenterology and 
hepatology specialists) in the DAA era found that only 15% were willing to treat people who 
were actively injecting drugs. Data have demonstrated excellent adherence and response to 
DAAs for HCV among people who recently used drugs (34–39), people receiving opioid 
substitution therapy (40–48), and people who recently injected drugs (49–51). Rates of 
reinfection among people who inject drugs are also relatively low (52, 53). In light of this 
evidence, there has been some debate as to the ethical justification for withholding therapy 
from people with ongoing drug or alcohol use (54).  
 
This study has several key implications for clinicians and policy makers. European countries 
should focus on removing restrictions that prevent primary care, and drug and alcohol care 
providers from prescribing DAAs. The 2016 EASL recommendations on treatment of 
hepatitis C provide guidance to ensure HCV is appropriately managed by health-care 
providers (12).  
 
Mobilisation of specialists to mentor and train primary care and drug and alcohol care 
providers, simplification of pathways for the referral of people with advanced liver disease 
(aspartate aminotransferase-to-platelet ratio index [APRI] >1) to specialists, and provision of 
HCV education and training for nurses, primary care providers, and drug and alcohol care 
providers would all help to increase access to reimbursed DAAs.  
 
The upcoming availability of pangenotypic DAAs will also make it easier for primary care and 
drug and alcohol care providers to prescribe DAAs. Although there is no one size fits all 
strategy for the widespread implementation of DAAs for HCV, a substantial increase in 
testing, linkage to care, and treatment—particularly among high-risk groups—will be required 
to reduce HCV incidence, HCV prevalence, and HCV-related morbidity and mortality (5, 17, 
55, 56).  
 
Efforts are needed to ensure appropriate monitoring and evaluation of country-level 
responses to HCV infection (which could then be added to national strategies and action 
plans) and the effect of DAA treatment uptake on HCV-related morbidity and mortality (18, 
57–59). Updated epidemiological data for the morbidity and mortality of HCV-related burden 
(14, 60) would probably further strengthen national level policy support for increased access 
to DAAs for HCV. Restrictions on DAA reimbursement throughout Europe are undoubtedly 
linked to the high list price of DAA regimens. As a result, current reimbursement restrictions 
in most European countries are related to prioritisation. The details of DAA prices (or 
discounts to list prices) are often not readily available, but there are considerable between-
country differences in the discounts to list prices across Europe. Broad access to DAAs 
requires negotiations to decrease DAA prices (or discounts to list prices) to facilitate removal 
of restrictions.  
 
Greater transparency regarding these negotiations and outcomes is important for the 
broader strategic development towards healthcare access for all. WHO mortality and 
incidence elimination targets are achievable and cost-effective (61) in many countries but will 
require the collective efforts of researchers, health-care providers, policy makers, the 
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